Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 12:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group A, Penicillin Clear all
Completed Phase 2 Interventional Results available

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 1, 2026, 12:41 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement

NCT03333408
View directory record Official record
Conditions
Salivary Duct
Interventions
Postoperative Oral Antibiotics (Clindamycin or Augmentin)
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 4 Interventional

Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections

NCT00001658
View directory record Official record
Conditions
Autoimmune Disease, Mental Disorder, Obsessive Compulsive Disorder, Streptococcal Infection, Tic Disorder
Interventions
Amoxicillin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 12:41 PM EDT
Completed No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients

NCT02427932
View directory record Official record
Conditions
Drug Metabolism During Pregnancy
Interventions
Ampicillin, Ampicillin and Gentamicin, Gentamicin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 4 Interventional Results available

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

NCT05342532
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
Amoxicillin, Omeprazole, Clarithromycin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 1, 2026, 12:41 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Pre-Emptive Analgesia in Dental Implant Surgery

NCT03243032
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ibuprofen 600 mg, Local anesthetic Group 1, Placebo oral capsule, Local anesthetic Control
Drug
Lead sponsor
Satheesh Elangovan
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 1, 2026, 12:41 PM EDT
Recruiting Phase 4 Interventional

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

NCT06494072
View directory record Official record
Conditions
Community Acquired Pneumonia in Children
Interventions
Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Not applicable Interventional Results available

Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children

NCT01166945
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate Combination, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Year to 10 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 1, 2026, 12:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

NCT01244698
View directory record Official record
Conditions
Bacterial Infection, Anti-infective Agents, Breast Implantation
Interventions
Cefadroxil discontinued early, Cefadroxil until drain removal
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy

NCT00662987
View directory record Official record
Conditions
Tonsillectomy
Interventions
7 days of amoxicillin, 3 days of amoxcillin followed by 4 days of placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 4 Interventional

Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

NCT03283878
View directory record Official record
Conditions
Arthropathy of Knee, Antibiotic Prophylaxis
Interventions
Cefazolin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
San Francisco, California • Atlanta, Georgia • Towson, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Early Phase 1 Interventional

Antibiotics Prior to Mini-screw Implant Insertion

NCT03582605
View directory record Official record
Conditions
Inflammation at Mini-screw Insertion Site, Mobility, Mini-screw
Interventions
Amoxicillin, Placebo oral capsule
Drug
Lead sponsor
St. Louis University
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 1, 2026, 12:41 PM EDT
Not listed Phase 4 Interventional

Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

NCT04573504
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

NCT06131021
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases, Periodontal Pocket
Interventions
Amoxicillin, Metronidazole, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions
Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

NCT01127880
View directory record Official record
Conditions
Hemopneumothorax, Pneumothorax
Interventions
Ancef or Clindamycin, Placebo
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2010 · Synced Oct 1, 2026, 12:41 PM EDT
Recruiting Phase 4 Interventional

Allergy Delabeling in Antibiotic Stewardship - Intervention

NCT07133074
View directory record Official record
Conditions
Beta Lactam Allergy, Hematologic Malignancy
Interventions
RENEW-IN Algorithm for assessment of a beta-lactam intervention, EMR Review
Diagnostic Test · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening

NCT06563440
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Digital app and information system
Other
Lead sponsor
Makerere University
Other
Eligibility
Up to 5 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Phase 2 Interventional Results available

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 12:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Congenital Syphilis

NCT02353117
View directory record Official record
Conditions
Congenital Syphilis
Interventions
Congenital Syphilis Intervention Group
Behavioral
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
13 Years and older · Female only
Enrollment
60,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 1, 2026, 12:41 PM EDT